Amgen and AstraZeneca have racked up their third straight Phase III win for brodalumab in plaque psoriasis, beating J&J’s Stelara in a head-to-head study. The news comes just two weeks after the pharma partners posted their latest positive results, positioning them for a run at regulators on both sides of the Atlantic.

…read more

Source: Amgen, AstraZeneca’s brodalumab beats J&J’s Stelara in 2nd PhIII psoriasis showdown